Recent cases of severe toxicity during clinical trials have been associated with antiviral ribonucleoside analogs (e.g. INX-08189 and balapiravir). Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis. Others have proposed that the prodrug moiety released from the ribonucleoside analogs might instead cause toxicity. Here, we report the mitochondrial effects of several clinically relevant and structurally diverse ribonucleoside analogs including NITD-008, T-705 (favipiravir), R1479 (parent nucleoside of balapiravir), PSI-7851 (sofosbuvir), and INX-08189 (BMS-986094). We found that efficient substrates and chain terminators of POLRMT, such as the nucleoside triphosphate forms of R1479, NITD-008, and INX-08189, are likely to cause mitochondrial toxicity in cells, while weaker chain terminators and inhibitors of POLRMT such as T-705 ribonucleoside triphosphate do not elicit strong in vitro mitochondrial effects. Within a fixed 3'-deoxy or 2 0 -C-methyl ribose scaffold, changing the base moiety of nucleotides did not strongly affect their inhibition constant (K i ) against POLRMT. By swapping the nucleoside and prodrug moieties of PSI-7851 and INX-08189, we demonstrated that the cell-based toxicity of INX-08189 is mainly caused by the nucleoside component of the molecule. Taken together, these results show that diverse 2 0 or 4 0 monosubstituted ribonucleoside scaffolds cause mitochondrial toxicity. Given the unpredictable structureactivity relationship of this ribonucleoside liability, we propose a rapid and systematic in vitro screen combining cell-based and biochemical assays to identify the early potential for mitochondrial toxicity.
Introduction
Nucleoside analogs play an important role in the fight against viral diseases. Recently, the approval of sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection has opened the door to the development of ribonucleoside analogs against HCV and other RNA viruses (Herbst and Reddy, 2013; McQuaid et al., 2015) . The main attributes of nucleoside analogs such as sofosbuvir are 1) a broad antiviral spectrum typically covering all strains of the same virus and 2) a high barrier to resistance (McCown et al., 2008) . Unfortunately, a number of ribonucleoside analogs have failed at various stages of preclinical and clinical development due to safety and toxicity concerns. For example, valopicitabine (NM283, ester prodrug of 2 0 -C-Me-C) and balapiravir (R1626, ester prodrug of 4'-azido-C), two anti-HCV cytidine analogs, could not be advanced beyond phase 2 studies due to gastrointestinal and hematological toxicity, respectively (Brown, 2009; Nelson et al., 2012) . The clinical development of INX-08189 (BMS-986094), a monophosphate prodrug of 2'-methyl-6-methoxy-guanosine intended for the treatment of chronic hepatitis C, was also halted due to severe cardiac toxicity that had not been previously identified through preclinical pharmacology profiling (Gentile et al., 2015) . The anti-dengue 7-deaza -2'-ethynyl--adenosine (NITD-008) also demonstrated safety concerns in animals that were not predicted from in vitro assessments (Yin et al., 2009) . These examples show that ribonucleoside toxicity tends to be compound specific and therefore not associated with any particular nucleobase, sugar, or phosphate prodrug modification, making it difficult to predict in the early stages of medicinal chemistry programs. Furthermore, these examples highlight the need to develop new in vitro assays to assess the potential safety liability associated with ribonucleoside analogs.
Attempts to better understand and prevent toxicity of nucleoside analogs have often revealed a lack of selectivity against human polymerases, as exemplified with HIV therapeutics targeting DNA polymerase gamma (Bienstock and Copeland, 2004; Cote, 2005; Feng et al., 2001; Johnson et al., 2001) . The ribonucleoside triphosphate forms of the HCV inhibitors balapiravir and INX-08189 are also known to be substrates of human mitochondrial RNA polymerase (POLRMT), blocking mitochondrial RNA transcription and protein synthesis (Arnold et al., 2012) . These offtarget enzyme-inhibitor interactions involving ribonucleotides were confirmed to be relatively specific to POLRMT and did not involve other human DNA or RNA polymerases except RNA polI (Feng et al., 2016) . The unwanted POLRMT-specific targeting by balapiravir and INX-08189 might be explained by the lack of structural similarity between the POLRMT and other human polymerases, and the hypothesized unique bacteriophage origin of POLRMT (Ringel et al., 2011; Shutt and Gray, 2006) . Importantly, balapiravir and INX-08189 were also associated with mitochondrial toxicity in cells, whereas sofosbuvir did not cause mitochondrial inhibition at the biochemical or cellular level (Arnold et al., 2012; Feng et al., 2016) . This proposed mechanism involving POLRMT as the main off-target interaction has been used to explain the toxicity of other ribonucleoside analogs (Fenaux et al., 2016) , but has also been contested by others. In particular, a direct link between the in vitro effects of INX-08189 on mitochondria and the cardiotoxicity observed in humans and animals has been difficult to establish (Ahmad et al., 2015; Baumgart et al., 2016; Feng et al., 2017; Gill et al., 2017) . Instead, the prodrug moiety of INX-08189 may be responsible for the observed toxicity, a mechanism that does not involve POLRMT (Ehteshami et al., 2016) . These separate and sometimes conflicting reports highlight the necessity to study the underlying root of toxicity of ribonucleoside analogs and to further de-risk mitochondrial toxicity in the early stages of antiviral drug development.
To better understand the structure-activity relationship responsible for mitochondrial toxicity, we evaluated a structurally diverse set of clinically relevant ribonucleoside analogs targeting different viruses (Fig. 1) . The molecules include the previously characterized HCV inhibitors R1479, INX-08189, and PSI-7851; the anti-influenza drug T-705 (favipiravir) (Baranovich et al., 2013; Furuta et al., 2002 , 2005 , 2009 , Oestereich et al., 2014 ; and the anti-dengue and anti-zika nucleoside analog, NITD-008 (Deng et al., 2016; Yin et al., 2009) . The in vitro effect of each molecule on mitochondrial RNA synthesis was compared with the POLRMT interaction and inhibition profile of their corresponding triphosphate metabolites. In addition, we measured the effect of changing the base moiety of 3'-deoxy and 2 0 -C-methyl nucleotides on the POLRMT inhibition constant (K i ). Finally, we evaluated the potential impact of the monophosphate prodrug by swapping the nucleoside and prodrug moieties of PSI-7851 and INX-08189 and measuring the mitochondrial toxicity of the resulting hybrid molecules.
Materials and methods

Reagents
Natural nucleoside triphosphates, ATP, CTP, GTP and UTP, were purchased from Trilink (San Diego, CA). Radiolabeled nucleoside triphosphates were purchased from PerkinElmer (Waltham, MA). All nucleoside analogs, their prodrugs and 5 0 -O-triphosphates used in this study were synthesized at Alios BioPharma, Inc (South San Francisco, CA) Tris-HCl buffer, NaCl and MgCl 2 solutions were purchased from Life Technologies. Trichloroacetic acid (TCA) (20% w/v) was purchased from BDH (Radnor, PA). Human mitochondrial RNA polymerase (POLRMT), human mitochondrial transcription factor A (TFA), human mitochondrial mitochondrial transcription factors B2 (TFB2) were purchased from Indigo Biosciences (State College, PA). Oligonucleotide pAA and pAAAGA were purchased from Dharmacon (Lafayette, CO).
Gel-based nucleotide incorporation by POLRMT using short DNA templates
The oligonucleotides required for the POLRMT assay were custom synthesized at Dharmacon and contained the following sequence: (primer) 5 0 -UUUUGCCGCGCC-3 0 , (template 1) 3 0 -CGGCGCGGTACG-TAAGGG-5 0 , and (template 2) 3 0 -CGGCGCGGCACGTAAGGG-5 0 , (template 3) 3 0 -CGGCGCGGGTACTAAGGG-5 0 , (template 4) 3 0 -CGGCGCGGATCGTAAGG G-5'. The DNA-dependent RNA polymerase (DdRp) assay with POLRMT was performed under single-turnover conditions where enzyme concentration is in excess of the primer/ template. Therefore, the 33 P-RNA/DNA primer/template was used at 100 nM together with 320 nM enzyme. The standard 10-mL reactions were carried out at 30 C for 1 min with 100 mM of each NTP, 10 mM MgCl 2 , 50 mM NaCl, 40 mM Tris, pH 7.5, and 1 mM dithiothreitol (DTT). The reaction was stopped by adding 20 mL of formamide loading dye containing 50 mM EDTA. RNA products were resolved by electrophoresis on 22.5% TBE-Urea polyacrylamide sequencing gels. The radiolabeled band was quantified using a Typhoon PhosphorImager and ImageQuant 5.2 software.
Abbreviations NITD-008-TP 7-deaza-2 0 -C-ethynyl -adenosine triphosphate INX-08189-TP 2 0 -C-methyl-guanosine triphosphate PSI-7851-TP 2 0 -Fluoro-2 0 -C-methyl-uridine triphosphate T-705 RTP T-705 ribofuranosyl triphosphate R1479-TP4 0 -azido-cytidine triphosphate ATP Adenosine triphosphate GTP Guanosine triphosphate UTP Uridine triphosphate CTP Cytidine triphosphate 2 0 -C-Me-UTP 2 0 -C-methyl uridine triphosphate 2 0 -C-Me-CTP 2 0 -C-methyl cytidine triphosphate 3 0 -dATP 3 0 -deoxy adenosine triphosphate 3 0 -dGTP 3 0 -deoxy guanosine triphosphate 3 0 -dCTP 3 0 -deoxy cytidine triphosphate 3 0 -dUTP 3 0 -deoxy uridine triphosphate COX-I cytochrome c oxidase I DdRp DNA-dependent RNA polymerase DTT Dithiothreitol HCV hepatitis C virus POLRMT human mitochondrial RNA polymerase K i inhibition constant NTP nucleoside triphosphate SDH-A succinate dehydrogenase A TCA trichloroacetic acid 2.3. Gel-based POLRMT transcription assay using long DNA templates A 325 bp long DNA was designed as the substrate for the POLRMT transcription assay. The DNA sequence was constructed with mitochondrial light strand promoter (LSP) at its 5'-end followed by transcription initiation site (underlined) and random filler sequences. The sequence was: 5 0 -GGAAAA-TAATGTGTTAGTTGGGGGGTGACTGTTAAAAGTGCATACCGCCAAAA-GAGGTCAAATCCAAATCAGCAAGCATGTCAAAGACGTGGGCCTGCCG AGCATCCATACCCCGACGAAGACGAAACTGCAACCGAGCGTGTTTTAT GACATCTTCCCGGGTAGTAAAGAACCGGCGGTGCTGACCGAAAAGGAT CCGCGTCTGAAAGTTGATTTTGACTCCGCCCTGTTCTCAAAGTATAAAG GCAACACCGAATGCTCACTGAATGAACATATTCAGGTCGCAGTGGCT CACTACTCGGCACAACTGGCTACGCTGGATATC. The DNA was inserted into a pUC57 plasmid for Maxiprep and the DNA segment was amplified by PCR using a forward primer (5 0 -GGAAAAT AATGTGT-TAGTTGGGGGG) and a reverse primer (5 0 -GATATCCAGCGTAGC-CAGTTG). The PCR product was served as the DNA template for the POLRMT transcription reactions. Each 10 mL reaction contained 10 mM Tris-HCl pH 7.4, 10 mM DTT, 10 mM MgCl 2 , 0.4 U/mL RNaseIn (Promega), 20 mM NaCl, 0.1 mg/mL bovine serum albumin (BSA), 10 nM DNA template, 0.083 mM 33P-GTP, 10 mM ATP, 1 mM GTP, 10 mM CTP, 10 mM UTP, and 80 nM POLRMT in the presence or absence of 100 mM pAA or 100 mM pAAAGA. Each reaction was kept at 30 C for 1 h and was quenched by adding 20 mL of formamide loading dye containing 50 mM EDTA. RNA products were resolved by electrophoresis on a 6% TBE-Urea polyacrylamide sequencing gels. The radiolabeled band was quantified using Typhoon PhosphorImager and ImageQuant 5.2 software.
Filter plate-based POLRMT transcription assay development and measurement of NTP K m values
Time dependence of POLRMT RNA transcription activity was measured by the incorporation of radioactively labeled nucleotides into acid-insoluble RNA products. Each 50-mL reaction contained 10 mM Tris-HCl pH 7.4, 10 mM DTT, 10 mM MgCl 2 , 0.4 U/mL RNaseIn (Promega), 20 mM NaCl, 0.1 mg/mL BSA, 10 nM DNA template, 0.5 mM tritiated UTP (36.3 Ci/mmol), 10 mM GTP, 10 mM ATP, 10 mM CTP, and POLRMT and pAAAGA at various concentrations as indicated in Fig. 3B . The reactions were incubated at 30 C and were measured every 30 min by quenching each 50-mL reaction with 60 mL 20% (w/v) TCA with 0.5 mM ATP. The quenched reactions were incubated at 4 C for at least 1 h. The reactions were loaded onto a 96-well filter plate (EMD Millipore; Billerica, MA). The filters on the plate were washed three times with 10% TCA and once with 70% ethanol on the Millipore plate wash station with vacuum applied. The filters on the plate were air-dried and 40 mL Microscint-20 was added into each well. The acid-precipitated RNA products on the plate were detected by a MicroBeta Trilux (PerkinElmer). The K m for each NTP with POLRMT was measured under the same reaction conditions except for holding other NTP concentrations at 100 mM and increasing the concentration of the testing NTP from 0 to 100 mM. Tritiated CTP was used in the K m measurement for UTP. Reactions were incubated at 30 C for 2 h.
Inhibition of POLRMT transcription by NTP analogs
The RNA transcription activity of POLRMT was measured by the incorporation of radioactively labeled nucleotides by POLRMT into acid-insoluble RNA products. Each reaction mixture contained 10 mM Tris-HCl pH 7.4, 10 mM DTT, 10 mM MgCl 2 , 0.4 U/mL RNaseIn (Promega), 20 mM NaCl, 0.1 mg/mL BSA, 10 nM DNA template, 10 nM pAAAGA, 1.5 mM ATP, 0.2 mM GTP, 0.5 mM CTP, 0.5 mM tritiated UTP (36.3 Ci/mmol), 20 nM POLRMT and testing compound at various concentrations. The reaction mixtures were incubated for 2 h at 30 C and were quenched with a cold mixture of 20% (w/v) TCA and 0.5 mM ATP. The quenched reactions were incubated at 4 C for at least 1 h and then the reactions were loaded onto a 96-well filter plate (EMD Millipore) for filter plate-based radiometric analysis as described in Section 2.4. The compound concentration at which the transcription activity of POLRMT was reduced by 50% (IC 50 ) was calculated by nonlinear regression data fitting using the equation,
where Y corresponds to the inhibition percentage, %Min and %Max are the inhibition percentages at low and at saturating compound concentration, respectively, and X is the log of the testing NEAA mixture, and 1% HEPES. U937 and MT4 cells were cultured in RPMI-1640 supplemented with 10% (v/v) FBS, 1% (v/v) penicillin/ streptomycin, 1 Â GlutaGro, 1% NEAA mixture, and 1% HEPES. All cells were maintained at 37 C in a humidified 5% CO 2 atmosphere.
Mitochondrial protein synthesis assay
To assess the long-term effect on mitochondrial protein synthesis, PC-3 cells were incubated with the viral polymerase inhibitors for 5 days. Stock solutions of 50 mM compounds were prepared in A. Top, the sequences of the RNA primer and the DNA template used in this set of reactions. Bottom, the sequencing gel image showing the incorporation of ATP analogs opposite TMP on the template and the chain termination effect of ATP analogs (þUTP) opposite T-dA on the template. B. Top, the sequences of the RNA primer and the DNA template used in this set of reactions. Bottom, Incorporation of GTP analogs opposite dC on the template and the chain termination effect of GTP analogs (þUTP) opposite dC-dA on the template. C. Top, the sequences of the RNA primer and the DNA template used in this set of reactions. Bottom, Incorporation of CTP analogs opposite dG on the template and the chain termination effect of CTP analogs (þATP) opposite dG-T on the template. D. Top, the sequences of the RNA primer and the DNA template used in this set of reactions. Bottom, Incorporation of UTP analogs opposite dAMP on the template. dimethyl sulfoxide (DMSO; Sigma Cat. #D2650) and stored at À20 C. On the day prior to treatment, 15,000 cells per well were plated in 90 mL in 96-well plates. The following day, compounds were diluted in media to 10 Â final concentration, and 10 mL was added in triplicate to the cells for a final volume of 100 mL, with 0.2% DMSO at the highest compound concentration. Duplicate sets of plates were prepared using the same compound dilutions. Cells were incubated undisturbed for 5 days at 37 C and 5% CO 2 . After 5 days, one set of plates was analyzed by adding 100 mL CellTiter-Glo (Promega G7573) and measuring luminescence on a Victor Â3 plate reader. The second set of plates was fixed in 4% paraformaldehyde prior to analysis using the MitoTox MitoBiogenesis in-cell enzyme-linked immunosorbent assay (ELISA) kit (Abcam ab110217), which simultaneously quantitates levels of mitochondrial DNA-encoded cytochrome c oxidase I (COX-1) and nuclear DNA-encoded succinate dehydrogenase A (SDH-A) within the cell.
8-Day cytotoxicity assay
To assess the long-term effect on cell proliferation and viability, the viral polymerase inhibitors were tested with six different human cell lines (Huh-7, HepG2, A549, HeLa, U937, and MT4) over an 8-day incubation period. Stock solutions of 50 mM compounds were prepared in DMSO (Sigma Cat. #D2650) and stored at À20 C. The day prior to compound treatment, cells were plated in 96-well plates in 90 mL culture media. A549, HeLa, HepG2, and Huh-7 cells were plated at 1000 cells/well, MT4 cells were plated at 10,000 cells/well, and U937 cells were plated at 2000 cells/well. The following day, compounds were solubilized in 100% DMSO at 50 mM and diluted in Dulbecco's Modified Eagle Medium (DMEM) to 10 Â final concentration. Compounds were serially diluted (1:3) up to 9 distinct concentrations in DMEM. A 10-mL aliquot of each compound was added to cells in triplicate for a final volume of 100 mL. The final DMSO concentration was 0.2% at the highest drug concentration. Cells were incubated for 8 days at 37 C and 5% CO 2 . Promega's CellTiter-Glo Luminescent Cell Viability Assay (Cat. #G7572) was used to measure cell viability. CellTiter-Glo reagent (100 mL) was added to each well and incubated at room temperature for 10 min. Luminescence was recorded using a PerkinElmer multilabel counter Victor Â3. The CC 50 , the concentration of the drug required to reduce the number of viable cells by 50% in relation to the untreated cell control value, was calculated from the plot of percentage reductions of the optical density value against the drug concentrations using XLFit function embedded in Microsoft Excel.
Results
Incorporation of Ribonucleotide analogs by POLRMT and chain termination effect
Recombinant POLRMT was used to measure the incorporation of antiviral ribonucleotide analogs following previously established methods (Arnold et al., 2012) . In an enzymatic assay designed for adenosine analogs, natural ATP was efficiently recognized as substrate by POLRMT, extending the 12-mer primer to a 13-mer product ( Fig. 2A, lane 2) . The ribofuranosyl triphosphate of T-705 (T-705 RTP) was efficiently incorporated into RNA at a level similar to ATP (Fig. 2A, lane 4) . NITD-008-TP was incorporated less efficiently, nevertheless more than the mis-incorporation of GTP opposite dT on the template DNA ( Fig. 2A, lanes 6 & 8) . Adding the next correct nucleotide (UTP) resulted in full primer extension (13-mer to 14-mer) for both ATP and T-705 RTP, but not for NITD-008-TP, which behaved like the obligated chain terminator 3'-dATP ( Fig. 2A, lanes 3, 5, 7, & 12) . Using a primer-template sequence designed for guanosine analog incorporation, natural GTP was efficiently incorporated by POLRMT, extending the 12-mer primer to a 13-mer product (Fig. 2B, lane 2) . T-705 RTP and INX-08189-TP (i.e. 2 0 -C-Me-GTP) were weakly incorporated, at a lower level than the mis-incorporation of ATP opposite dC on the template (Fig. 2B,  lanes 4, 6, & 10) . Adding the next correct nucleotide (UTP) together with the GTP analog resulted in further primer extension for GTP (13-mer to 15-mer) and T-705 RTP (13-mer to 14-mer), but not for INX-08189-TP (2 0 -C-Me-GTP) (Fig. 2B, lane 3, 5 & 7) . The obligate chain terminator, 3 0 -dGTP, was efficiently incorporated and completely inhibited subsequent primer extension when UTP was added (Fig. 2B, lanes 8 & 9) . Compared with the lane of UTP misincorporation, the weak band of 14-mer product with INX-08189-TP/U most likely came from mis-incorporation of UTP (Fig. 2B,  lanes 7 & 11) . Using a primer-template sequence designed for cytosine analogs, R1479-TP was incorporated efficiently and caused inhibition of further primer extension in the presence of the next correct nucleotide ATP (Fig. 2C, lanes 4 & 5) . Using a primertemplate sequence designed for uridine analog incorporation, PSI-7851-TP (i.e. 2 0 -F-2 0 -C-Me-UTP) was not incorporated under In these reactions, DNA, POLRMT and pAAAGA were incubated and aliquots from the reaction were withdrawn at indicated time points and processed by acid precipitation followed by filter capture. C. K m measurement of the natural nucleoside triphosphates. The K m value for each NTP was measured by incubating the reaction mixtures with all other NTPs at 100 mM and increasing the experimental NTP concentration from 0 to 100 mM. The data of product vs testing NTP concentration was fitted to the Michaelis-Menten equation to derive the K m value. One representative experiment is shown. The K m values for ATP, GTP, CTP and UTP, were 0.92 ± 0.6 mM, 0.13 ± 0.09 mM, 0.27 ± 0.17 mM, 0.78 ± 0.48 mM, respectively.
The average and standard deviation were from two independent experiments. this assay condition (Fig. 2D, lane 3) .
In summary, T-705 RTP was incorporated into RNA as both an ATP and a GTP analog, but did not result in immediate chain termination. In contrast, incorporation of NITD-008-TP, R1479-TP, and INX-08189-TP resulted in chain termination for all three nucleotides. PSI-7851-TP was not incorporated into RNA by POLRMT so the potential for chain termination could not be determined.
Development of a 96-well plate primer-extension assay for POLRMT
Our use of a short artificial RNA/DNA substrate in the gel-based POLRMT assay was limited to semi-quantitative evaluation of nucleotide incorporation and chain termination. Therefore, we developed a higher-throughput plate-based assay to measure the overall inhibition effect of nucleotide analogs competing with natural NTPs.
Efficient POLRMT RNA transcription has been shown to require a DNA template with specific promoter sequence and transcription factors including TFA and TFB2 (Lodeiro et al., 2010) . We designed a DNA template of approximately 350 bases containing the mitochondrial light strand promoter at the 5'-end to establish a long RNA transcription assay. Using this DNA template, POLRMT synthesized RNA efficiently either in the presence (Fig. 3A, lanes 1, 3, 5) or absence (Fig. 3A, lanes 2, 4, 6 ) of mitochondrial transcription factors TFA and TFB2. Short RNA primers dramatically increased the RNA transcription activity of POLRMT. The pAAAGA primer boosted the level of RNA synthesis more than the pAA primer (Fig. 3A , comparing overall RNA products in lanes 3, 4 to lanes 5, 6). These two primers were complementary to the template DNA strand at the transcription start site, so POLRMT could use these short RNA as primers for more efficient RNA synthesis, bypassing the inefficient de novo synthesis of the first several nucleotides on the nascent RNA primer strand. Since POLRMT catalyzed RNA synthesis efficiently with the help of primers in the absence of transcription factors, transcription factors were not included in the following POLRMT RNA synthesis assays. Further characterization of the time courses of RNA transcription from the DNA template using POLRMT and pAAAGA at various concentrations demonstrated the optimal assay condition was 20 nM POLRMT and 10 nM pAAAGA for the POLRMT RNA transcription assay (Fig. 3B) . The time course of RNA transcription under the optimized condition was linear up to 150 min and the signal-to-background ratio was approximately 18-fold at 120 min. Based on the above characterization, we established this 96-well plate primer-extension assay with the aim to measure, under steady-state kinetics, the competitive inhibition of POLRMT RNA transcription in the presence of NTP analogs.
Inhibition of POLRMT transcription activity by NTP analogs
In the primer-extension POLRMT transcription assay, 3 H-UTP was used as the tracer and other natural nucleotides were added at concentrations near their K m value, which was 0.92 mM for ATP, 0.13 mM for GTP, 0.27 mM for CTP and 0.78 mM for UTP (Fig. 3C ). This assay condition was then validated with all four canonical 3 0 deoxynucleoside triphosphates (3'-dNTPs) which terminate RNA elongation immediately after their incorporation due to a lack of 3 0 -OH group on their ribose moiety. The concentrations of 3'-dNTPs resulting in 50% of maximum inhibition (IC 50 ) of POLRMT RNA synthesis were 2.3 mM for 3'-dATP, 0.41 mM for 3'-dGTP, 2.8 mM for 3'-dCTP and 2.7 mM for 3'-dUTP ( Fig. 4A and of 221 mM and a K i of 84 mM (Fig. 4B) . NITD-008-TP and INX-08189-TP inhibited POLRMT with IC 50 values of 91 mM and 32 mM, respectively. R1479-TP demonstrated the strongest inhibition of POLRMT with an IC 50 of 2.6 mM and a K i of 0.9 mM. As expected, PSI-7851-TP exhibited almost no inhibition of POLRMT transcription (Fig. 4B) .
It had been shown that modified 2 0 -C-methyl-NTP analogs are efficiently incorporated by POLRMT and cause immediate chain termination (Arnold et al., 2012) . All four 2 0 -C-Me-NTPs were thus Table 1 . (Table 2 ). In contrast, 2 0 -C-Me-UTP did not inhibit POLRMT at concentrations up to 300 mM.
Effect of nucleoside analogs on mitochondrial protein synthesis
Inhibition of POLRMT activity may reduce RNA transcription in mitochondria, leading to a decrease in mitochondrial protein synthesis in cells. To study the correlation between POLRMT inhibition observed in biochemical assays and mitochondrial protein synthesis in cells, we studied the reference nucleoside analogs in PC-3 cells. It has been demonstrated that the prostate cell line PC-3 cells are more sensitive to mitochondrial toxicity than the hepatic cell line, HepG2 (Feng et al., 2017) . PC-3 cells were treated with nucleoside analogs and other non-nucleoside control compounds for 5 days. At the end of treatment, the amount of mitochondrialencoded protein COX-1 and nuclear-encoded protein SDH-A were quantified. The cellular ATP level was also recorded to monitor the cell viability (Fig. 5) . Chloramphenicol specifically inhibited COX-1 expression with little effect on SDH-A or ATP level up to 100 mM, in agreement with its known inhibitory effect on the mitochondrial ribosome. The dideoxyribonucleoside ddC also specifically inhibited COX-1 expression, which is consistent with its previously Fig. 5 . Effect of nucleoside analogs on mitochondrial protein synthesis in PC-3 cells. PC-3 cells were treated with compounds for 5 days. The synthesis of the mitochondrial DNA-encoded protein, cytochrome c oxidase I (COX-I), and the nuclear DNA-encoded mitochondrial protein, succinate dehydrogenase A subunit (SDH-A) were monitored using the MitoBiogenesis™ In-Cell ELISA kit. Cell viability monitored as ATP level was measured using the CellTiter-Glo ® assay kit. In each plot, the percentages of the levels of COX-I (C, red), SDH-A (-, blue) and ATP (:, green) relative to their levels in the controls (no compound treatment) was plotted against the concentration of each compound indicated on the xaxis. Chloramphenicol and ddC were used as controls for specific inhibition of COX-1 synthesis; while puromycin was a control for general cytotoxicity. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) described inhibition of mitochondrial DNA polymerase (pol gamma) leading to reduced mitochondrial DNA replication (Feng et al., 2001 (Feng et al., , 2017 . In comparison, puromycin, which binds to ribosome and causes termination of all protein translation, inhibited COX-1, SDH-A synthesis, and ATP formation with similar profiles. Overall, the behavior of the control compounds was also consistent with previously published data (Feng et al., 2017) . Among our test compounds, T-705 and PSI-7851 did not inhibit protein synthesis and had no effect on ATP levels in cells. As expected from its known toxicity towards mitochondria, R1479 specifically inhibited COX-1 synthesis. In contrast, NITD-008 and INX-08189 inhibited all three markers, although INX-08189 was more potent than NITD-008 (Fig. 5, Supplementary Table 1 ).
8-day cytotoxicity in a panel of human cell lines
The toxicity of the nucleoside analogs was further profiled across 6 human cell lines. Cells were treated with compounds for 8 days, and cell viability was measured using the CellTiter-Glo assay kit, which measures intracellular ATP levels. All CC 50 values are reported in Table 3 . T-705 did not demonstrate cytotoxicity against any of the 6 cell lines, at concentrations up to 100 mM. 3.6. Contribution of the prodrug moiety to cellular toxicity Two hybrid molecules were designed and synthesized to probe the effect of the monophosphate prodrug moieties on cell viability (Fig. 6A) . Hybrid-1 contains the core nucleoside of INX-08189 and the prodrug phenoxy-phosphorylamino propanoate isopropyl ester of PSI-7851, which can lead to the formation of 2 0 -C-Me-GTP in cells. Hybrid-2 contains the core nucleoside of PSI-7851 and the naphthalen-phosphorylamino propanoate prodrug of INX-08189, which can form 2 0 -F-2 0 -C-Me-UTP in cells. Importantly, both hybrid-1 and hybrid-2 potently inhibited HCV replication in the replicon assay, indirectly suggesting that the two compounds support active intracellular NTP formation (data not shown). Significant cytotoxicity associated with hybrid-1 treatment was observed in 5 cell lines (CC 50 < 50 mM), with the exception of A549 cells that were consistently the most resilient (CC 50 ¼ 74 mM) (Table 4 ). In contrast, hybrid-2 strongly decreased the viability of U937 cells only, at a CC 50 value similar to that of PSI-7851 (6 versus 18 mM). The effect of these two hybrid prodrugs on mitochondrial protein synthesis was also determined. The protein synthesis inhibition profile of hybrid-1 was similar to INX-08189 (Fig. 6B and Suppl. Table 1 ) whereas hybrid-2 only weakly inhibited COX-1 protein synthesis and ATP formation at concentrations of 100 mM Table 3 CC 50 of nucleoside analogs in the 8-day toxicity study.
Cell Line
CC 50 (mM)
T-705 NITD-008 INX-08189 R1479 PSI-7851 A549 >100 >100 10.8 ± 3.8 >100 >100 HeLa >100 94 ± 8 8.1 ± 2.6 20.2 ± 1.1 >100 HepG2 >100 28 ± 17 1.7 ± 0.1 >100 >100 Huh7 >100 >74 ± 36 0.34 ± 0.15 >100 >100 MT4 >100 30 ± 4 3.0 ± 0.1 52 ± 22 >100 U937 >100 >73 ± 37 <0.015 4.1 18.0 Fig. 6 . Effect of the hybrid nucleoside analogs on mitochondrial protein synthesis in PC-3 cells. Assays were conducted as described in Fig. 5 and in Section 2.6. A. compound hybrid-1 contains 2 0 -Me-GMP as its parent and the same prodrug modification used in sofosbuvir. Hybrid-2 contains 2 0 -F-2 0 -Me-UMP as its parent and the same prodrug modification used in INX-08189. B. In each plot, the percentages of the levels of COX-I (C, red), SDH-A (-, blue) and ATP (:, green) relative to their levels in the controls (no compound treatment) was plotted against the concentration of each compound indicated on the x-axis. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
( Fig. 6B and Supplementary Table 1) .
Discussion
Impairment of mitochondrial function is increasingly recognized as an underappreciated cause of drug toxicity, which has resulted in post-market drug withdrawals Nadanaciva and Will, 2011) . The main objective of this study was to better understand the structureactivity relationship elements governing the mitochondrial toxicity of antiviral ribonucleoside analogs. This was fueled by the need to establish in vitro methods to predict the potential liabilities of ribonucleoside analogs early in the drug discovery process, before entering clinical trials. The study comprised three separate parts. Part 1 established and validated the in vitro assay methods using known and previously characterized antiviral ribonucleoside analogs with varying degrees of mitochondrial toxicity. Part 2 tested new compounds that had not been characterized previously.
Finally, part 3 aimed to gain general off-target structure-activity relationship knowledge by synthesizing novel hybrid molecules to explore the contribution of the nucleoside itself and the prodrug moiety on mitochondrial toxicity.
The uridine analog PSI-7851 was used as negative control because it did not induce mitochondrial toxicity in cells and its triphosphate form PSI-7851-TP was not recognized as substrate for POLRMT (Figs. 2D and 5) . The cytidine analog R1479 was used as positive control for ribonucleoside-induced mitochondrial toxicity. Although R1479 did not induce profound cell death in our standard panel of cell lines (Table 3) , it selectively inhibited the expression of the mitochondrial protein COX-1 (Fig. 5) . The effect of R1479 on cells was similar to that of chloramphenicol and ddC, two known toxicants of mammalian mitochondria (Birkus et al., 2002; McKee et al., 2006) . The mitochondrial toxicity of R1479 is supported by the observation that R1479-TP was recognized as substrate and a chain terminator of POLRMT (Fig. 2) . These results are in agreement with previous reports establishing a correlation between the offtarget POLRMT effect of R1479 and mitochondrial toxicity in cells (Arnold et al., 2012; Feng et al., 2017) . The guanosine analog INX-08189 was used as a second positive control in this study because its triphosphate form was also incorporated into RNA by POLRMT (Fig. 2) . The interpretation of the mitochondrial toxicity of INX-08189 was complicated by the fact that it is very toxic to cells even at low concentrations (Table 3) . Consistently, INX-08189 equally inhibited nuclear and mitochondrial DNA-encoded protein synthesis (Fig. 5) . These results are also in agreement with a previous study reporting the general toxicity of INX-08189 and highlight the difficulty of distinguishing mitochondrial-induced from other types of toxicities (Feng et al., 2017) . Feng et al. pointed out that INX-08189 caused an initial decrease in cell respiration prior to cell death, confirming the hypothesis that INX-08189 is toxic to mitochondria. Although functional in vitro assays measuring the impairment of cell respiration and oxidative phosphorylation have been successfully applied to non-nucleoside drugs acting as mitochondrial toxicants (Kamalian et al., 2015; Marroquin et al., 2007; Pereira et al., 2012; Swiss et al., 2013; Will and Dykens, 2014) , the effect of INX-08189 on oxygen consumption was rather subtle and prone to interpretation debate (Feng et al., 2017) . This example highlights the difficulty of differentiating mitochondrial toxicity of nucleoside analogs using cell-based assays (Baumgart et al., 2016; Gill et al., 2017) , and indicates the importance of POLRMT biochemical profiling in these types of studies. Others have shown that, although ribonucleoside analogs do not typically affect levels of mitochondrial DNA or cellular RNA, toxic molecules such as 2 0 -C-methyl-A or R1479 (4'-azido-C) significantly decrease the amount of mitochondrial RNA measured by Northern blot (Arnold et al., 2012) .
Since the gel-based format of the POLRMT assay is very low throughput and semi-quantitative, we developed a more quantitative plate-based POLRMT RNA synthesis assay. The sensitivity of the assay was optimized using a primer and under conditions in which transcription factors were no longer required (Fig. 3A and B) . We found 5-nucleotides to be the optimal primer length to support DdRp activity. Since the purpose of this assay was to determine the IC 50 and K i values of NTP analogs competing against their natural NTP counterpart, the sensitivity of the assay to compound inhibition had to be optimized by measuring the K m of each natural NTP (Fig. 3C ). Under these assay conditions, PSI-7851-TP did not inhibit POLRMT activity, consistent with the fact that PSI-7851-TP was not recognized as substrate by the human enzyme (Figs. 4B and 2D ). In comparison, R1479-TP and INX-08189-TP were inhibitors of POLRMT activity with K i values of 0.9 and 13 mM, respectively (Table 1) . This is also consistent with the observation that R1479-TP is more efficiently incorporated into RNA by POLRMT than INX- 08189-TP ( Fig. 2B and C) . By combining all biochemical and cell-based assay results, we established a simple color-coded chart to summarize the mitochondrial toxicity profile of ribonucleoside analogs for comparison with other molecules (Fig. 7A) . We previously showed that the influenza polymerase inhibitor T-705, in its ribofuranosyl triphosphate form, is recognized as substrate not only by RNA polymerases from other viruses such as norovirus, but also by POLRMT (Jin et al., 2015) . We now report that T-705 does not cause mitochondrial toxicity in cells under our assay conditions (Fig. 5) . Our data suggest that although T-705 RTP is incorporated into RNA by POLRMT, this does not result in chain termination or inhibition of the DdRp activity ( Fig. 2A, B and 4B) . The potential mutagenic effect of T-705 on mitochondrial gene transcription and translation is unknown, which could be addressed in future studies. Overall, T-705 does not have the typical profile of a mitochondrial toxic nucleoside in our assays (Fig. 7A ), but its potential toxicity effect on mitochondria should not be ignored since T-705, like 6-methylpurine, is an efficient substrate of POLRMT (Arnold et al., 2012) . Unlike T-705, the triphosphate form of the dengue inhibitor, NITD-008, was not only recognized as substrate by POLRMT, but its chain termination effect resulted in inhibition of the POLRMT activity in the primer extension assay, with a K i value of 34 mM (Figs. 2A and 4B, Table 1 ). The biochemical profile of NITD-008 agreed with its toxicity in the panel of cell-based assays ( Fig. 5 and Table 3 ), and was reminiscent of the overall characteristics of INX-08189 (Fig. 7A) . Our interpretation is that, although NITD-008 does not have the same mitochondrial effect as R1479, the 2 0 -C-ethynyl adenosine analog has the potential to cause mitochondrial toxicity. It should be noted that the general toxicity of nucleosides in PC-3 cells was only measured for 5 days, instead of 8 days for the other cell lines (Table 3) . Despite this limitation, our result is in overall good agreement with the recent report that a structurally related 2 0 -Cethynyl uridine prodrug also caused mitochondrial toxicity (Fenaux et al., 2016) . From this analysis, the emerging structure-activity relationship of mitochondrial toxicity indicates that 2 0 or 4 0 mono-substitutions on the sugar moiety of ribonucleoside analogs often do not provide sufficient differentiation between the viral and human polymerase (Fig. 7B) . The clinical relevance of this study could be enhanced by comparing these in vitro findings with the pharmacokinetics parameters of each parent nucleoside in vivo, and even more importantly by measuring the levels of nucleoside triphosphates susceptible to mitochondrial toxicity in multiple cell types and tissues from rodent and non-rodent animal species.
Combined with previous studies, our work with known and clinically relevant nucleoside analogs demonstrated that mitochondrial toxicity is not base-specific as all four nucleobases have been associated with toxic ribonucleosides (Feng et al., 2017) . This point was further emphasized with systematic testing of all 3'dNTPs and 2 0 -C-Me-NTPs in the POLRMT inhibition assay (Tables 1 and 2 ). It should also be pointed out that in our hands, uridine analogs were the least potent inhibitors among the four bases in the POLRMT assay, with K i values for 3'-dUTP and 2 0 -C-Me-UTP of 1.6 and > 183 mM, respectively. In an effort to further understand the structure-activity relationship of mitochondrial toxicity, we designed and synthesized two hybrid monophosphate prodrugs. Hybrid-1 containing the core nucleoside of INX-08189 and the prodrug of PSI-7851 was significantly more toxic than hybrid-2, which had the core nucleoside of PSI-7851 and the prodrug of INX-08189 (Fig. 6 ). This result indicates that the toxicity of INX-08189 is predominantly mediated by the core nucleoside part of the molecule. However, we cannot exclude that the prodrug moiety also contributes to some of the observed in vitro toxicity, which is supported by the observation that hybrid-1 is less toxic than INX-08189, and that hybrid-2 is more toxic than PSI-7851. For this reason, we propose that all ribonucleoside analogs, irrespective of their nucleobase, sugar modification, and prodrug moiety, be screened in vitro for their potential to cause mitochondrial toxicity.
